medical 21

Medical 21 develops the MAVERICS graft, an artificial artery built to replace vein harvesting in bypass surgery, reducing risks, recovery time, and costs while expanding treatment access to millions of patients worldwide.

features

  • Medical 21 is developing a biocompatible artificial artery to eliminate the need for vessel harvesting in heart bypass surgery. Founded by Manny Villafaña, the company aims to transform coronary artery bypass graft (CABG) procedures worldwide.  
  • A medtech company pioneering an artificial, biocompatible artery to replace vein harvesting in coronary artery bypass graft surgeries, aiming to make operations safer, faster, and more accessible worldwide.  

Biocompatible Artificial Artery

Developing an artificial artery to replace harvested veins in CABG surgery, reducing pain, scarring, and recovery time.

Heart Disease Challenge

Cardiovascular disease is the #1 cause of death worldwide, with nearly 1 million CABG surgeries performed each year.

Current CABG Limitations

Vein harvesting increases pain, risk of infection, longer recovery, and has high failure rates.

MAVERICS Graft System

A regenerative, biocompatible, and thrombo-resistant artificial artery designed to be flexible, strong, and long-lasting.

Proof of Concept

Animal studies surpassed the 90-day FDA requirement and continued over 180 days; human trials are being prepared.

Market Size

An estimated $8–10 billion market with a need for 2–3 million grafts per year worldwide.

Advantages Over Traditional CABG

Eliminates vein harvesting, reduces failure rates, shortens surgery and recovery times, and expands eligibility to more patients.

Primary Market

US hospitals and worldwide distribution with a partnership with Mayo Clinic.

Investment Opportunity

$5.80 per share, $116 minimum investment, $40M target raise through Regulation A offering.

Leadership Team

Includes experts in cardiovascular research, biomedical engineering, and manufacturing with decades of medical device experience.

Advisory Board

Renowned cardiac surgeons, biomedical engineers, and medtech business leaders advising product and market strategy.

Regulation A Disclaimer

SEC-qualified offering; investors should read the offering circular before investing.

technologies

  • Next.js
  • Tailwind CSS
  • TypeScript

Gallery

 medical 21 ghulamrasool ghulamrasool154 gr grsaddiqui ghulamrasool ghulamrasool154 gr grsaddiqui
 medical 21 ghulamrasool ghulamrasool154 gr grsaddiqui ghulamrasool ghulamrasool154 gr grsaddiqui
 medical 21 ghulamrasool ghulamrasool154 gr grsaddiqui ghulamrasool ghulamrasool154 gr grsaddiqui
 medical 21 ghulamrasool ghulamrasool154 gr grsaddiqui ghulamrasool ghulamrasool154 gr grsaddiqui
 medical 21 ghulamrasool ghulamrasool154 gr grsaddiqui ghulamrasool ghulamrasool154 gr grsaddiqui
 medical 21 ghulamrasool ghulamrasool154 gr grsaddiqui ghulamrasool ghulamrasool154 gr grsaddiqui